For: | Fazio N. Watch and wait policy in advanced neuroendocrine tumors: What does it mean? World J Clin Oncol 2017; 8(2): 96-99 [PMID: 28439490 DOI: 10.5306/wjco.v8.i2.96] |
---|---|
URL: | https://www.wjgnet.com/2218-4333/full/v8/i2/96.htm |
Number | Citing Articles |
1 |
Jingjing Zhang, Qingxing Liu, Aviral Singh, Christiane Schuchardt, Harshad R. Kulkarni, Richard P. Baum. Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine 2020; 61(11): 1560 doi: 10.2967/jnumed.119.241414
|
2 |
Mirco Bartolomei, Alfredo Berruti, Massimo Falconi, Nicola Fazio, Diego Ferone, Secondo Lastoria, Giovanni Pappagallo, Ettore Seregni, Annibale Versari. Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. Cancers 2022; 14(10): 2501 doi: 10.3390/cancers14102501
|
3 |
Jaume Capdevila, Jorge Hernando, Santiago Perez-Hoyos, Alejandro Roman-Gonzalez, Enrique Grande. Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors. The Oncologist 2019; 24(12): e1315 doi: 10.1634/theoncologist.2018-0675
|
4 |
Francesco Panzuto, Angela Lamarca, Nicola Fazio. Comparative analysis of international guidelines on the management of advanced non-functioning well-differentiated pancreatic neuroendocrine tumors. Cancer Treatment Reviews 2024; 129: 102803 doi: 10.1016/j.ctrv.2024.102803
|